ARB users exhibit a lower fracture incidence than ACE inhibitor users among older hypertensive men
Publication in refereed journal

替代計量分析
.

其它資訊
摘要Introduction
angiotensin II, a major effector protein of the renin angiotensin system (RAS), induces bone loss under certain conditions. Drugs that block the RAS may therefore reduce bone loss and fracture incidence. The fracture incidence in older hypertensive men with long-term use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) were compared with the incidence in users of calcium channel blockers (CCBs) and non-users.

Methods
a total of 5,994 US men aged 65 years or older who had bone mineral density measured at baseline in the Osteoporotic Fractures in Men Study (MrOS) were followed for fracture incidence for an average of 6.8 years. Men with follow-up dual-energy X-ray absorptiometry bone mineral density data and who reported hypertension at any visit, or use of antihypertensive medications at any visit among those with non-missing mediation data were included in the study (N = 2,573).

Results
six hundred and nineteen men had taken ACE inhibitors, while 182 took ARBs for at least 4 years. Using Cox regression for the incidence of non-vertebral fractures, we found that long-term users of ACE inhibitors and ARBs each had a significantly lower fracture incidence than non-users. The hazard ratio of non-vertebral fractures was three times lower in ARB users than ACE inhibitor users (Hazard ratio (95% confidence interval): 0.194 (0.079–0.474) versus 0.620 (0.453–0.850), P = 0.0168). There was a trend of greater fracture risk reduction with longer duration of ARB use, but not for ACE inhibitor use.

Conclusions
in older hypertensive men, ARBs use was associated with lower incidence of non-vertebral fracture than ACE inhibitors or CCBs.
著者Timothy Kwok, Jason Leung, Elizabeth Barrett-Connor
期刊名稱Age and Ageing
出版年份2017
月份1
卷號46
期次1
出版社Oxford University Press
頁次57 - 64
國際標準期刊號0002-0729
語言英式英語
關鍵詞older people, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, fracture, hypertension, male, aged

上次更新時間 2021-20-09 於 00:27